

LA JOLLA CANCER RESEARCH FOUNDATION  
ANIMAL USAGE FORM



AUF 1413

1. PRINCIPAL INVESTIGATOR WAYNE A. BORDER, M.D.	OFFICE PHONE 226	HOME/EMERGENCY PHONE (714) 770-4602
2. OTHER INVESTIGATOR LUCIA LANGUINO, Ph.D.	230	519-0609
3. SENIOR TECHNICIAN		

4. PROJECT TITLE  
ANTI-HUMAN TGF $\beta$  CYCLIZED PEPTIDE

5. GRANT NUMBER, IF ANY 250300	NEW X	RENEWAL	PILOT	PROJECT NUMBER
-----------------------------------	----------	---------	-------	----------------

6. START DATE	END DATE	MICE	RATS	RABBITS 2	GP	OTHER (SPECIFY)
		QUANTITY				

7. PROJECT GOAL (SEE INSTRUCTIONS)  
To produce quantities of anti-human TGF $\beta$  cyclized peptide for use in kidney disease research.

8. RATIONALE (SEE INSTRUCTIONS)  
Rabbits produce high quality antiserum which can be used for identification of human TGF $\beta$  in tissue samples and in vitro assays to study progression of kidney injury.

9. DESCRIBE USE OF ANIMALS (SEE INSTRUCTIONS)  
All injections/bleedings to be performed by animal care facility personnel.  
1. Pre-bleeding 20 ml from ear vein.  
2. Inject 500  $\mu$ g TGF $\beta$  cyclized purified peptide (0.5 ml antigen in PBS + 0.5 ml FCA) subcutaneously in 2 sites.  
3. After one month, boost with 125  $\mu$ g antigen (0.25 ml antigen in PBS + 0.25 ml incomplete adjuvant) subcutaneously, 2 sites.  
4. After 10 days, bleed 50 ml from alternating ear veins 3 times.  
5. Repeat steps 1-4 at 4-6 week intervals.

10. PAIN LEVEL: A ☐ B ☐ C ☐


IF B OR C READ INSTRUCTIONS. PROVIDE DESCRIPTION OR JUSTIFICATION HERE:

CONFIDENTIAL

11. EUTHANASIA (SEE INSTRUCTIONS)	DURING PROJECT <input type="checkbox"/>	METHOD OR TECHNIQUE	CG. <input type="checkbox"/>	CERV. DISLOC. <input type="checkbox"/>	RETAIN CARCASSES YES <input type="checkbox"/>
	END OF PROJECT <input checked="" type="checkbox"/>		CG. <input checked="" type="checkbox"/>	OTHER (SPECIFY)	NO <input type="checkbox"/>

12. SIGNATURES

PI WABorde	DATE	U2 05334	DATE
AP MCA	DATE		



LJCRF

TODAY'S DATE:

This procedure relates to the project outlined on Animal Usage Form No. \_\_\_\_\_

12/13/88	50 ml	(If more than 8 procedures are required, attach a second form.)	5
12/16/88	"		6
12/21/88	Extra 100 ml		7
			8

Vol. of blood to be collected each procedure: ml.

RECEIVED  
MAR 15 2007

TECH CENTER 16440000



Injection of 2 rabbits with Linear FB-103 peptide  
no 86-87 from TGF $\beta$ .


2 " with lyophilized FB-103 u.  
no 88-89

~~2 rabbits~~

Procedure: 2 mg / rabbit of each peptide.

- 2 mg peptide were dissolved in 250  $\mu$ l DDW  
(added to the solution to couple the peptide)
- 0.5 mg Methylated BSA were ~~added~~ ~~to the solution~~ ~~to couple the peptide~~  
(Sigma A1003 : M<sub>2</sub>BSA)
- vortex 30''
- Added 250  $\mu$ l Forsk's conjugant complete
- mixed 1h with homogenizer.
- 0.5 ml solution was injected in each rabbit.

Note: Both peptides were difficult to dissolve.  
" " were not HPLC purified



Injection of 2 rabbits linear TGF $\beta$  peptide

Cytic

PG peptide

Procedure

except Ford's incomplete adjuvant was used

For unguine

KLH - peptide was already coupled

I only mixed to F.i. 80% in 14 L.C. inject 0.5 ml

Rabbit 7

n<sup>o</sup> 1284  
1285

for PG

ALF 1285